Search Within

Jennifer Kimberly Lue

Formats
  1. Meeting Abstract (36)
  2. Journal Article (11)
  3. Book Section (2)
  4. Research Letter (2)
  5. Review (2)
Groups
  1. Department of Medicine (46)
  2. Hematologic Malignancies, Division of (46)
  3. Center for Hematologic Malignancies (43)
  4. Lymphoma (43)
  5. Hematology-Oncology Fellows (36)
  6. GSK Faculty (33)

More Groups

People
  1. Gilles Salles (45)
  2. Lorenzo Falchi (41)
  3. Maria Palomba (39)
  4. Andrew Zelenetz (37)
  5. Anita Kumar (37)
  6. Paul Hamlin (33)

More People

Years
  1. 2025 (7)
  2. 2024 (22)
  3. 2023 (19)
  4. 2022 (5)
Publications
  1. Blood (33)
  2. Hematological Oncology (3)
  3. Leukemia and Lymphoma (3)
  4. Blood Advances (2)
  5. Blood Cancer Journal (2)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (35)
  2. Wiley Blackwell (5)
  3. Taylor & Francis Group (3)
  4. American Society of Clinical Oncology (2)
  5. Ferrata Storti Foundation (2)
  6. Nature Publishing Group (2)

More Publishers

Results (53)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis
    Journal Article

    Luttwak, E.; Robin, E. T.; Drill, E.; Boardman, A.; Caron, P.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma
    Review

    Lue, J. K.; Healton, S. E.; Salles, G. A.
    Trends in Cancer (2025)

    Fulltext@MSK | Save
  • Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience
    Journal Article

    Cassanello, G.; Luttwak, E.; Brown, S.; Devlin, S. M.; Imber, B.; Ip, A.; Leslie, L. A.; Accav, N. G.; Avigdor, A.; Marcus, R.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
    Journal Article

    Einarsdottir, S.; Lobaugh, S.; Luan, D.; Gomez-Llobell, M.; Subramanian, P.; Devlin, S.; Chung, D.; Dahi, P. B.; Falchi, L.; Giralt, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR T-cell therapy for DLBCL with CNS involvement: Overall safe and effective with limited efficacy in patients with leptomeningeal disease
    Meeting Abstract

    Luttwak, E.; Cassanello, G.; Brown, S.; Devlin, S. M.; Imber, B. S.; Ip, A.; Leslie, L. A.; Accav, N. G.; Beyar-Katz, O.; Corona, M.; more...
    Blood (2024)

    Fulltext@MSK | Save